“…Photodynamic therapy (PDT) with minimal invasion and high selectivity has attracted wide attention in cancer treatment. , In the PDT process, the photosensitizers could generate reactive oxygen species (ROS) that exhibit high cytotoxicity to broad-spectrum tumors upon illumination. , To date, the photosensitizers for PDT mainly consist of porphyrin and its derivatives, boron dipyrromethene (BODIPY) derivatives, and ruthenium (Ru)-based complexes. − BODIPY and its derivatives have attracted notable interest in PDT due to their excellent photophysical properties, such as strong visible absorption, high singlet oxygen quantum yields (QYs), and good photostability. ,,− Up to now, many BODIPY derivatives have been synthesized and exploited as fluorescent probes , or PDT photosensitizers. − However, there are some limitations to hinder their clinical translation. First, BODIPY derivatives exhibit a narrow Stokes shift of about 10 nm . This small Stokes shift could induce self-absorption in the solid or aggregation state.…”